ArticleCell stem cell2009
Genetic control of wayward pluripotent stem cells and their progeny after transplantation.
Article in Cell stem cell, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 64 citations in OpenAlex.
- Generation of neural cells from DM1 induced pluripotent stem cells as cellular model for the study of central nervous system neuropathogenesis.Cellular reprogramming · 2013Trial
- Strategies to Improve the Safety of iPSC-Derived β Cells for β Cell Replacement in Diabetes.Transplant international : official journal of the European Society for Organ Transplantation · 2022Review
- Improved safety of induced pluripotent stem cell-derived antigen-presenting cell-based cancer immunotherapy.Molecular therapy. Methods & clinical development · 2021Article
- Derivation and applications of human hepatocyte-like cells.World journal of stem cells · 2019Review
- Increased Cytotoxicity of Herpes Simplex Virus Thymidine Kinase Expression in Human Induced Pluripotent Stem Cells.International journal of molecular sciences · 2019Article
- Stem cells and their potential clinical applications in psychiatric disorders.Progress in neuro-psychopharmacology & biological psychiatry · 2018Review
- Tumor prevention facilitates delayed transplant of stem cell-derived motoneurons.Annals of clinical and translational neurology · 2016Article
- Escape Mutations, Ganciclovir Resistance, and Teratoma Formation in Human iPSCs Expressing an HSVtk Suicide Gene.Molecular therapy. Nucleic acids · 2016Article
- The Application of Human iPSCs in Neurological Diseases: From Bench to Bedside.Stem cells international · 2016Review
- Review
- Werner Syndrome-specific induced pluripotent stem cells: recovery of telomere function by reprogramming.Frontiers in genetics · 2015Review
- Human pluripotent stem cell-derived retinal pigmented epithelium in retinal treatment: from bench to bedside.Molecular neurobiology · 2014Review
- Cell and tissue engineering for liver disease.Science translational medicine · 2014Review
- 'Above all, do no harm': safeguarding pluripotent stem cell therapy against iatrogenic tumorigenesis.Stem cell research & therapy · 2014Article
- Pluripotent stem cells in regenerative medicine: challenges and recent progress.Nature reviews. Genetics · 2014Review
- Development of an inducible caspase-9 safety switch for pluripotent stem cell-based therapies.Molecular therapy. Methods & clinical development · 2014Article
- Stability of genomic imprinting in human induced pluripotent stem cells.BMC genetics · 2013Article
- Targeting of herpes simplex virus 1 thymidine kinase gene sequences into the OCT4 locus of human induced pluripotent stem cells.PloS one · 2013Article
- Embryonic stem cells for severe heart failure: why and how?Journal of cardiovascular translational research · 2012Review
- The challenge of using gene- or cell-based therapies to treat lung disease.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The proliferative capacity of pluripotent stem cells and their progeny brings a unique aspect to therapeutics, in that once a transplant is initiated the therapist no longer has control of the therapy. In the context of the recent FDA approval of a human ESC trial and report of a neuronal-stem-cell-derived tumor in a human trial, strategies need to be developed to control wayward pluripotent stem cells. Here, we focus on one approach: direct genetic modification of the cells prior to transplantation with genes that can prevent the adverse events and/or eliminate the transplanted cells and their progeny.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.